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http://dx.doi.org/10Epigenetic changes can contribute to development of acute myeloid leukemia (AML), a ma-
lignant disease of the bone marrow. A single-nucleotide polymorphism of transcription fac-
tor growth factor independence 1 (GFI1) generates a protein with an asparagine at position
36 (GFI136N) instead of a serine at position 36 (GFI136S), which is associated with de novo
AML in humans. However, how GFI136N predisposes to AML is poorly understood. To
explore the mechanism, we used knock-in mouse strains expressing GFI136N or GFI136S.
Presence of GFI136N shortened the latency and increased the incidence of AML in different
murine models of myelodysplastic syndrome/AML. On a molecular level, GFI136N induced
genomewide epigenetic changes, leading to expression of AML-associated genes. On a ther-
apeutic level, use of histone acetyltransferase inhibitors specifically impeded growth of
GFI136N-expressing human and murine AML cells in vitro and in vivo. These results estab-
lish, as a proof of principle, how epigenetic changes in GFI136N-induced AML can be
targeted. Copyright  2016 ISEH - International Society for Experimental Hematology.
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Epigenetic changes that may lead to gene expression
changes play an important role in the development of
normal and malignant hematopoiesis [1–6]. Recent findings
suggest that mutations in several transcription factors or
even small alterations of their expression levels could influ-
ence the development and prognosis of acute myeloid leu-
kemia (AML) [5,7–12]. GFI1 is a zinc finger transcriptional-senior authors.
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.1016/j.exphem.2016.05.004repressor that recruits histone-modifying enzymes, such as
histone deacetylases, to its target genes [13]. GFI1 regulates
key functions of hematopoietic stem cells (HSCs) [13–15],
as well as myeloid–lymphoid lineage decision [14,16–20].
A variant form of the GFI1 gene (denominated GFI136N),
generated by a single-nucleotide polymorphism, is associ-
ated with a predisposition to develop de novo AML in
Caucasian patients [21]. To further examine the association
between GFI136N and AML, we generated mouse
‘‘knockin’’ strains, in which we substituted the endogenous
murine Gfi1-coding sequences with the human GFI136N or
GFI136S gene [22]. GFI136N-expressing mice featured
distinct changes in the hematopoietic system compared
with GFI136S- or Gfi1WT-expressing mice. They are charac-
terized by an increased number of bone marrow (BM)
monocytes and granulocytic monocytic progenitor cells
(GMPs), a population, from which leukemic stem cellsatology. Published by Elsevier Inc. This is an open access article under the
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GFI136N-expressing mice developed a Kras-mediated
myeloproliferative disorder within a shorter period than
GFI136S-expressing mice [22]. In all observations, the pres-
ence of one allele of GFI136N was sufficient to induce these
different changes, pointing to a dominant effect of GFI136N.
This again resembles the situation in humans, as most
GFI136N-expressing AML patients are heterozygous for
GFI136N [21].
To assess the role of GFI136N in AML development and
to explore the mechanisms underlying these findings, we
used these ‘‘knockin’’ mouse strains expressing endoge-
nously human GFI136N or GFI136S and crossed them with
different transgenic animals prone to develop AML, resem-
bling the human diseases. Presence of GFI136N shortened
the latency period and increased the incidence of AML
development in all mouse models used. On a molecular
level, the presence of GFI136N was associated with
increased levels of acetylation of histone 3 at lysine 9
(H3K9ac), which is associated with active transcription,
at GFI1 target genes. Bioinformatics analyses revealed
that these genes are involved in roles such as cell prolifer-
ation and transcription in both human and murine AML
samples. Furthermore, we illustrate, as a proof-of-
principle, that treatment with histone acetyltransferase in-
hibitors (HATis) specifically targets GFI136N leukemic
cells, suggesting that therapies with HATis might improve
the poor prognosis of GFI136N patients.Methods
Mice and antibodies
Mice carrying the human GFI136N and GFI136S cDNA, instead of
the murine Gfi1 gene, were generated as previously described [22].
Mice were backcrossed for more than 20 generations into a
C57BL/6J background. The efficiency of backcrossing was veri-
fied by satellite-specific polymerase chain reaction (PCR) [24].
We initially confirmed a similar phenotype in two different
founder strains for each genotype. No major differences were
observed between different founder strains with the same genetic
background. The conditional Cbfb-MYH11 AML mouse strain
(also called CBFbeta-SMMHC) was kindly provided by Dr. Lucio
H. Castilla. To induce Cbfb-SMMHC expression in vivo, heterozy-
gous mice were crossed with Mx1-Cre transgenic mice and with
either GFI136N or GFI136S knock-in mice. Primary triple heterozy-
gous mice at 6–8 weeks of age were injected intraperitoneally
every other day with seven doses of polyinosinic polycytidylic
acid (poly(I:C), Sigma-Aldrich) at a dose of 500 mg per injection.
Mx-Creþ and the NUP98-HOXD13 myelodysplastic syndrome
(MDS) mouse models were purchased form Jackson Laboratory
(Bar Harbor, ME). All mice were housed under specific path-
ogen–free conditions. The German Ethics Committee for Animal
Use approved all experiments under Document G1196/11. BM
and spleen cells from sick mice were analyzed by flow cytometry
(fluorescence-activated cell sorting [FACS]) using the following
anti-mouse antibodies from Biolegend: Ly-6G/Ly-6C (Gr-1),
CD11b, CD8a, CD4, TER-119/Erythroid Cells Antibody,CD45R/B220 and CD117(c-Kit). Apoptosis was measured by
staining the cells with Annexin V (BD Bioscience or Biolegend).
Inhibitor administration
A 30-mg/mL stock of Histone Acetyltransferase Inhibitor VII,
CTK7a (Millipore) and a 50-mg/mL stock of Vorinostat (SAHA,
Sigma-Aldrich) were prepared in dimethyl sulfoxide (DMSO)
and stored at 20C in 160-mL aliquots until further use. For
the in vivo inhibitor trial, 5  104 GFP-positive cells from
leukemic primary recipient mice transplanted with MLL-AF9-
transduced GFI136S or GFI136N cells were injected intravenously
into sublethally irradiated (3 Gy) C57Bl/6J mice. Two days post-
transplantation, mice were injected intraperitoneally every other
day with six doses of 38 mg/kg CTK7a or 50 mg/kg Vorinostat.
Control mice were injected with vehicle (DMSO). For the
ex vivo treatment experiment, fresh leukemic BM cells were iso-
lated from leukemic mice previously transplanted with MLL-
AF9–expressing cells derived from different genotypes. The cells
were cultured for 48 hours in SCM medium containing 50 mmol/L
CTK7a or vehicle (DMSO), and 100,000 GFP-positive cells were
transplanted into sublethally irradiated congenic mice.
For in vitro studies, CD34þ cells from peripheral blood (PB) or
BM of AML patients collected before initiation of treatment were
isolated using the Human CD34 Positive Selection Kit (StemCell
Technologies). For patients with no CD34þ cells, a Dead Cell
Removal Kit (Miltenyi) was used to isolate the live cells before
treatment. Approximately 7  104 to 1  105 cells per well
were seeded in a 96-well non–tissue culture-treated plate
(100 mL/well) using Iscove’s modified Dulbecco’s medium
(Gibco, Life Technologies) supplemented with 20% fetal bovine
serum (FBS; Pan Biotech), 1% Pen/Strep (Sigma), and 10 ng/
mL of each of the following cytokines: human stem cell factor
(SCF), human FLT3 ligand, human thrombopoietin (TPO; all
from Miltenyi Biotec). The cells were then exposed to varying
concentrations of CTK7a and Vorinostat. After 48 hours of treat-
ment, the live cells were counted and stained with Annexin V
(Biolegend) to measure the level of apoptosis.
ChIP and ChIP-Seq analysis
Chromatin immunoprecipitation sequencing (ChIP-Seq) assays
were performed as previously described [25] using a polyclonal
H3K9acetyl (Abcam) antibody. For more details, please refer to
the Supplementary Materials and Methods (online only, available
at www.exphem.org) [22,26].
Gene expression arrays and mutational analysis
Gene expression arrays were performed according to published
procedures [22]. Gene set enrichment analysis (GSEA) was per-
formed by comparing each GFI136S-heterozygous or -homozygous
hematopoietic progenitor or leukemic cells with its GFI136N coun-
terpart against all curated gene sets in the Molecular Signature
Database. For more details, please refer to the Supplementary
Materials and Methods.
Gene expression array data from human AML/MDS samples
are deposited under GEO No. 58831. The next-generation
sequencing performed on the cohorts was described in the original
publications [27–29].
Statistical methods
Significance of differences in percentages was determined using
the two-sample t test. Other statistical analyses were done using
715L. Botezatu et al./ Experimental Hematology 2016;44:713–726either paired or unpaired two-sided t tests. For survival of murine
cohorts, the Gehan–Breslow–Wilcoxon test was used. All p values
reported are two-sided and considered to indicate significance at
#0.05. All analyses presented were performed using GraphPad
Prism 5 or 6 software (GraphPad Software, La Jolla, CA) or
SPSS Version 19 (IBM, Armonk, NY).Results
GFI136N promotes AML development in murine models
To examine whether, indeed, the presence of GFI136N ac-
celerates AML development, we used two mouse strains
in which the endogenous Gfi1-encoding sequence (abbrevi-
ated as Gfi1WT/WT) is replaced by the human GFI136N or
GFI136S cDNA [22]. GFI136N alone was not sufficient to
induce leukemia [22]. We therefore examined whether ad-
ditive effects between GFI136N and drivers of leukemia
development exist. Because 99% of MDS and AML
GFI136N carriers are heterozygous for this variant [22],
we used heterozygous knock-in mice that have only one
allele of human GFI136N or GFI136S; the other allele is mu-Figure 1. Role of GFI136N allele in the development and progression of MDS/A
with aMLL-AF9-expressing retrovirus from GFI136N/WT or GFI136S/WT mice were
cells as described in (A) after culturing 5,000 GFPþ cells for 7–10 days in liquid m
in (A) after culturing 1,000 GFP-positive cells for 7–10 days in semisolid medium
AF9-expressing retrovirus (1  105 GFPþ cells) were transplanted alongside 1.5
Kaplan–Meier curve of AML-free survival is shown. Confidence interval (CI) 5
per nanoliter blood of sacrificed mice described in (D). (F) One representative cell
mice described in (D) with respect to the expression of surface proteins Gr-1 and Crine Gfi1. GFI136N or GFI136S animal groups differ only
with respect to one single amino acid at position 36 in
the expressed human proteins, minimizing other confound-
ing effects. In all leukemic models described below,
GFI136N/36N mice did not differ from GFI136N/WT leukemic
mice with respect to leukemia survival. Similarly,
GFI136S/36S leukemic mice did not differ from GFI136S/WT
or GFI1WT/WT mice with respect to survival.
To assess the influence of GFI136N on the expansion of
preleukemic cells in vitro, we tested the additional effects
between concomitant expression of different human oncofu-
sion proteins and GFI136N. One example is MLL-AF9, the
protein product of the t(9;11)(p22;q23) translocation, which
is recurrently found in a subset of AML patients and serves
as a model of human AML development in mice [30].MLL-
AF9–expressing cells containing GFI136N/WT exhibited
enhanced expansion in vitro as compared with the same
cells containing GFI136S/WT (Fig. 1A and B) or GFI1WT/WT
(data not shown) and gave rise to a larger number of col-
onies in colony-forming cell (CFC) assays (Fig. 1C). In
agreement with previous findings [22], this was aML. (A) Schematic of the experimental design. Lin– BM cells transduced
either used for transplantation or sorted for CFC assay. (B) Total number of
edium. *p5 0.01. (C) Total number of colonies in CFC assay as described
. *p5 0.02. (D) Lin– GFI136N/WT or GFI136S/WT cells transduced withMLL-
 105 wild-type competitive BM cells, into lethally irradiated mice. The
1.2–12.8; p 5 0.04. (E) Analysis of WBC count, with the number of cells
surface marker analysis (FACS) of the GFPþMLL-AF9 blast cells from the
D11b. (G) Cytospins of the BM from mice described in (D). Bar5 20 mm.
Figure 1. (continued) (H) Kaplan–Meier curve of AML-free survival of GFI136N/WT and GFI136N/N (n 5 24), GFI136S/WT and GFI136S/S (n 5 22) NUP98-
HOXD13 transgenic mice. CI 5 1–7; p 5 0.04. (I) Analysis of WBC counts in the peripheral blood of deceased mice described in (H). (J) A representative
FACS plot of the BM of leukemic mice described in (H) with respect to Gr-1 and CD11b expression. (K) Cytospins of the BM from mice described in (H).
Bar5 20 mm. (L) Kaplan–Meier curve of AML-free survival of GFI136N/WT and GFI136N/N (n5 30), GFI136S/WT and GFI136S/S (n 5 20) Cbfb-MYH11-Inv16
mice. CI 5 1.6–6.6; p 5 0.001. (M) Analysis of WBC counts in the peripheral blood of the deceased mice described in (J). (N) Representative FACS plot of
the BM of leukemic mice described in (J) with respect to CD117 expression. (O) Cytospins of the BM from mice in (L). Bar 5 20 mm.
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apoptosis rates. In addition, mice transplanted with
GFI136N/WT cells expressing MLL-AF9 succumbed faster
to leukemia than mice transplanted with the equivalent
GFI136S/WT (Fig. 1D; p 5 0.04) or Gfi1WT/WT cells (data
not shown). There was no significant difference with
respect to white blood cell (WBC) count, surface marker
expression, or cytology (Fig. 1E–G). Diagnosis of leukemia
was based on appearance of blast cells (Fig. 1G), compro-
mised function of the BM of the affected mice as a result of
infiltration with malignant cells, and leukocytosis
(Supplementary Figure E1A–E, online only, available at
www.exphem.org), according to established criteria for
the diagnosis of murine AML [31]. Thus, GFI136N pro-
motes growth of leukemia in mice as compared with
GFI136S.
We have recently reported that the presence of GFI136N
accelerates progression to AML in patients with MDS [32].
MDS is characterized by disturbed development of the he-
matopoietic system. It results in cytopenia or can progress
to AML [33–38]. To verify the role of GFI136N in a murine
model of human MDS, we used transgenic mice expressingNUP98-HOXD13 [39], mimicking the t(2;11)(q31;p15)
translocation found in human AML. These mice develop
a disease similar to human MDS [39] with blast cells in
the BM, dysplastic features of myeloid cells, increased
apoptosis rates, as well as progressing cytopenia. Similar
to the human situation, a fraction of these mice develop leu-
kemia reminiscent of AML, with concomitant reduced
function of BM and appearance of blast cells in the PB,
whereas the remaining animals die from cytopenia [39].
GFI136N shortened the latency period and increased the
incidence of AML in these animals (p5 0.04) (Fig. 1H) ac-
cording to criteria mentioned above (Supplementary
Figure E2A–E, online only, available at www.exphem.
org). There was no significant difference with respect to
WBC count, surface marker expression, or cytology
(Fig. 1I–K) in the leukemic cohorts of both groups.
To further confirm the negative influence of GFI136N on
AML development, we used another mouse strain in which
expression of the oncofusion protein Cbfb-MYH11 can be
conditionally switched on, recapitulating the inv(16)/
t(16;16) translocation associated with AML [40]. Also in
this model, the presence of GFI136N accelerated AML
717L. Botezatu et al./ Experimental Hematology 2016;44:713–726development with shorter latency periods and higher inci-
dence as compared with Cbfb-MYH11-transgenic animals
carrying only GFI136S alleles (p 5 0.001) (Fig. 1L), having
an increased number of leukemic blasts in PB
(Supplementary Figure E3A–E, online only, available at
www.exphem.org). As in the other models, there was no
difference with respect to WBC count, surface marker
expression, or cytology in either cohort (Fig. 1M–O).
Presence of GFI136N is associated with epigenetic
changes
GFI1 is a transcriptional repressor that recruits, among
other factors, histone deacetylases (HDACs) to its target
genes [13]. Given that GFI136N differs from GFI136S with
respect to its ability to induce epigenetic changes at the
Hoxa9 locus [22], we first investigated the effect of
GFI136N at the epigenetic level in the Cbfb-MYH11 model,
because differences in survival and incidence between
GFI136N and GFI136S leukemic cells were most prominent.
We performed RNA-Seq on GFI136N- and GFI136S-hetero-
zygous murine AML samples and, using GSEA, we found
pathways enriched for chromatin modification in GFI136N
samples (data not shown). Because H3K9 and H3K14 acet-
ylation are both markers for active transcription [41], we
correlated published genomewide ChIP-Seq data of GFI1
binding in murine leukemic cells [25] (Fig. 2A) with
ChIP-Seq data for H3K9 and H3K14 acetylation in normal
hematopoietic progenitor cells from GFI136N- and GFI136S-
expressing mice. Our analysis indicated that the presence of
GFI136N was associated with higher levels of H3 acetyla-
tion around transcription start sites (TSSs) of previously
identified GFI1 target genes when compared with
GFI136S (Fig. 2B, set 0). Because GFI1 is known to influ-
ence H3K9 deacetylation [22], we next examined whether
murine GFI136N leukemic samples also exhibit a higher
level of H3K9 acetylation. We observed a higher level of
H3K9 acetylation at the TSSs of a set of 1,470 GFI1 target
genes in GFI136N versus GFI136S leukemic cells in two of
three sample sets (Fig. 2C, D, sets 1–3), with Hoxa9 among
these genes (Supplementary Figure E4A, B, online only,
available at www.exphem.org). Functional analysis re-
vealed that these genes significantly belong to various cell
cycle, transcriptional, and chromatin regulation pathways
(Fig. 2E), whereas genes downregulated in acetylation are
linked to DNA repair and intracellular signaling
(Supplementary Figure E5A, online only, available at
www.exphem.org). H3K9 acetylation levels and mRNA
expression positively correlated overall (Supplementary
Figure E5B). Among GFI1 target genes exhibiting
increased H3K9 acetylation levels in GFI136N-expressing
cells, a corresponding increase in mRNA expression levels
was found in 63%, 74%, and 90% of cases for sample pairs
1–3, respectively (Fig. 2F). At genes associated with AML
development and with higher acetylation enrichment,
Meis2, Tcf4, and Irf8, an increase in correspondingmRNA expression was further confirmed by reverse
transcription PCR in GFI136N versus GFI136S leukemic
cells (Supplementary Figure E6A–C, online only, available
at www.exphem.org).
A similar H3K9 acetylation ChIP-Seq analysis was per-
formed with primary human AML cells from GFI136N/36S
and GFI136S/36S patients (Supplementary Table E1, online
only, available at www.exphem.org). The results indicated
significantly increased H3K9 acetylation at the TSSs of a
specific set of 1,686 genes in GFI136N/S-heterozygous over
GFI136S/S-homozygous cells (Fig. 3A, Supplementary
Table E1). A functional GO pathway analysis revealed
that these 1,686 genes are significantly involved in tran-
scription, chromatin regulation, and Ras protein signalling
(Fig. 3B). Genes downregulated in acetylation are signifi-
cantly linked to translation and RNA splicing
(Supplementary Figure E7A, online only, available at
www.exphem.org). Here, as well, the changes in histone
acetylation positively correlated with changes in mRNA
levels (Fig. 3C, Supplementary Figure E7B). Furthermore,
among genes with an increase in promoter acetylation, a
corresponding increase in mRNA levels was observed in
81% and 80% of genes for pairs 4 and 5, respectively
(Fig. 3C). Genes with increased acetylation and expression
in both human sample pairs were involved in cell activation,
differentiation, and transcription (Fig. 3D).
The increased levels of H3K9 acetylation are not due to
impaired binding of GFI136N to different HDACs
(Supplementary Figure E8A, B, online only, available at
www.exphem.org). Also, despite a high variation in GFI1
expression level in human AML patients (Supplementary
Figure E9A, B, online only, available at www.exphem.
org) [42,43], murine Gfi1 and human GFI1 expression level
were similar for GFI136N- and GFI136S-expressing cells in
different murine models of human AML (Supplementary
Figure E9C–H).
We next investigated which epigenetic alterations were
induced in the murine NUP98-HOXD13 model of human
MDS that may progress to AML. We determined genome-
wide acetylation levels of H3K9 in murine BM cells ex-
pressing either GFI136N or GFI136S (the other allele being
murine Gfi1). Similar to the AML model results, we
observed an increased level of H3K9 acetylation among
GFI1 target genes (Fig. 4A) in GFI136N heterozygous sam-
ples compared with GFI136S heterozygous samples. In
GFI136N heterozygous samples, genes with increased acet-
ylation of H3K9 at promoters were enriched in pathways
associated with AML development or inferior prognosis
of AML (Fig. 4A). To test whether a similar pattern can
be found among samples from MDS patients, we analyzed
published gene expression arrays of MDS patients [27–29]
with respect to the presence of GFI136N. We observed that
the presence of GFI136N was associated with a stem cell
signature, which had previously been found to be associated
with poor prognosis [5] and with pathways indicative of
Figure 2. GFI136N leads to epigenetic changes in murine AML samples. (A–C) ChIP-Seq results for a set of 1,470 genes identified as GFI1 targets and found
to haveO1.5-fold increase in acetylation in GFI136N samples in two or more pairs of samples from the Cbfb-MYH11model (C). (A) GFI1 enrichment relative
to an IgG control. Rows represent a 4-kb window centered on the TSS of a single gene. Below is the average distribution of GFI1 binding across all selected
GFI1 target genes. (B) H3K9ac ChIP-seq enrichment (relative to H3 control) for selected genes on Lin–c-Kitþ cells derived from GFI136S or GFI136N homo-
zygous mice. Rows represent a 2.5-kb window for a single gene. Below is the average distribution of acetylation across all selected genes. GFI136S is in blue
and GFI136N is in red. (C) H3K9ac ChIP-seq enrichment (relative to H3 control) for selected genes between leukemic cells derived from Cbfb-MYH11-trans-
genic animals carrying either GFI136S or GFI136N allele (n 5 3 for each genotype). Below is the average distribution of H3K9ac across all selected genes.
(D) Venn diagram of GFI1 target genes revealing aO1.5-fold increase in H3K9ac in GFI136N samples in three different pairs derived from the Cbfb-MYH11
model. (E) Functional analysis of genes revealing a 1.5-fold increase in acetylation in two or more sample pairs, as illustrated in (D). GO biological processes
were identified using DAVID. The p value was used to rank the enrichment. (F) Scatterplot comparing the log2-fold change in H3K9 acetylation between
Cbfb-MYH11 GFI136S and Cbfb-MYH11 GFI136N leukemic samples (y axis) versus the log2-fold change in mRNA expression between the same leukemic
samples (x axis), revealing only genes with greater than 1.5-fold change, for three pairs of samples. (Color version of figure available online.)
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corroborating our results from human and murine AML
samples.
Presence of GFI136N alters responses to epigenetic
therapy
Our data, as well as previous reports [22], indicate that
GFI136Nmaynot recruitHDACs to a subset of its target genesas efficiently as GFI136S, which could contribute to a faster
progression of AML. Immunoprecipitations from 293T cells
transfected with vectors for either protein variant contained
HDAC1 and HDAC2 for both (Supplementary Figure E8A,
B), indicating that GFI136N is still bindingHDACs. Although
both GFI136N and GFI136S interact with HDACs 1 and 2, we
cannot entirely rule out that in another context, a differential
interaction between GFI1 and these HDACs or other de-
Figure 3. GFI136N leads to epigenetic changes in human AML samples. (A) ChIP-Seq analysis of leukemic blasts from patients homozygous for
GFI136S or heterozygous for GFI136N (n 5 2 for each genotype). Heat maps illustrate H3K9ac enrichment relative to an H3 control for genes ex-
hibiting a O1.5-fold increase in acetylation in the GFI136N sample in both sample pairs. Each row represents a 2.5-kb window, extending 0.5 kb
and þ2 kb from the gene TSS. Below, a plot illustrates the average distribution of H3K9ac relative to the TSS across all selected genes. GFI136S is in
blue and GFI136N is in red. (B) Functional analysis of genes revealing a 1.5-fold increase in acetylation in both human AML sample pairs as
described in (A). GO biological processes were identified using DAVID. The p value was used to rank enrichment. (C) Scatterplot comparing the
log2-fold change in H3K9 acetylation (ChIP-Seq) between GFI1
36S and GFI136N human leukemia samples (y axis) versus the log2-fold change in
mRNA expression (RNA-Seq) between GFI136S and GFI136N human leukemia samples (x axis), illustrating only genes with greater than 1.5-fold
change, for three pairs of samples. (D) Functional analysis of genes revealing a 1.5-fold increase in acetylation, as well as a 1.5-fold increase in
expression in both sample pairs. GO biological processes were identified using DAVID. The p value was used to rank enrichment. (Color version
of figure available online.)
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Figure 4. Model of pathophysiologic function of GFI136N in MDS/AML and a possible therapeutic intervention. (A) ChIP-Seq analysis of leukemic blasts
from NUP98-HOXD13 transgenic mice heterozygous for GFI136S or GFI136N. Genes exhibiting a greater than twofold increase in acetylation in the GFI136N
sample were further analyzed. The genes that are known to be GFI1 target genes and that play a role in myeloid development [24] were first examined. A plot
indicates the average distribution of H3K9ac relative to the TSSs across all selected genes. GFI136S is in blue, and GFI136N is in red. Reads were normalized to
total read counts. We also performed GSEA on all genes, which revealed a greater than twofold increase in acetylation in the GFI136N samples, irrespective of
whether they are GFI1 target genes or not (normalized enrichment score [NES] 5 1.8 for Jaatinen HSCs, p 5 0.001; NES 5 1.7 for Valk AML cluster 10,
p 5 0.02; NES 5 2 for GFI1 binding sequence, p 5 0.001; NES 5 1.7 for Ivanova HSCs, p 5 0.001). (Jaatinen, Valk and Ivanova are the names for datasets
from the molecular signatures database [MSIGDB]). (B) Functional analysis of genes revealing a 1.5-fold increase in acetylation in both human AML sample
pairs as described in (A). GO biological processes were identified using DAVID. The p value was used to rank enrichment. (C) Working model hypothesis: In
GFI136S homozygous patients there is normal acetylation at GFI1 target genes, and the use of HDACis is an effective therapy for GFI136SMDS/AML patients.
(D) In GFI136N heterozygous/homozygous patients, GFI136N still binds histone-modifying enzymes, but it does not recruit them efficiently to its target genes.
This leads to overacetylation at GFI1 target genes and upregulation of GFI1 target genes involved in leukemia initiation. (E) HATis could rebalance the dys-
regulated epigenetic modifications and be more beneficial for GFI136N hetero-/homozygous MDS/AML patients. (Color version of figure available online.)
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721L. Botezatu et al./ Experimental Hematology 2016;44:713–726acetylating enzymesmay exist. It is likely that the previously
reported lower efficiency of GFI136N binding to the target
genes compared with GFI136S [22] is responsible for the
lower level of histone deacetylation seen in cells expressing
GFI136N. It is conceivable that if deacetylation of certain
genes is impeded by the presence of GFI136N, additional
use of an HDAC inhibitor (HDACi), as used in experimental
epigenetic therapies ofAML,might not be beneficial, leading
to overacetylation at GFI1 target genes in contrast to the
situation in which only GFI136S is expressed (Fig. 4C, D).
We hypothesized that the use of an HATi might be more suit-
able and could rebalance the effect of impaired deacetylation
in GFI136N-expressing cells (Fig. 4E). If this were the case,
treatment of leukemic cells with HDACis or HATis would
have a different effect in GFI136N versus GFI136S murine
or human leukemic cells. It is possible, for instance, that
GFI36N leukemic cells would not respond to treatment with
HDACis but would respond to treatment with HATis. To
test this, we treated MLL-AF9-leukemic cells from
GFI136N/WT or GFI136S/WT mice with Vorinostat, an HDACi
(reviewed by Lane and Chabner (2009) [44]), or with
CTK7a, an HATi [45] (Fig. 5A), at low concentrations com-
parable to physiologically in vivo attainable concentrations,
thus minimizing toxic effects on the cells [45,46]. Although
GFI136S/WT-expressing cells exhibited 70% growth reduction
after treatment with Vorinostat, GFI136N/WT-expressing cells
were refractory to this treatment (Fig. 5A). In contrast, treat-
ment ofGFI136N-expressing cells with CTK7a caused a 60%
reduction in cell numbers (Fig. 5A). Similarly, GFI136S/WT
leukemic cells originating from Cbfb-MYH11-expressing
leukemic mice responded well to treatment with HDACis,
whereasGFI136N/WT cells were not affected by this treatment
but responded to a greater extent toHATi treatment (Fig. 5B),
suggesting a more pronounced antiproliferative effect of
CTK7a specifically on GFI136N leukemic cells.
On a molecular level, we used Cbfb-MYH11-expressing
cells to test the effect of Vorinostat and CTK7a on the pro-
moter acetylation of Hoxa9 and Meis2 oncogenes, two ex-
amples of GFI1 target genes. As we described in our
model (Fig. 4C–E), we expect that treatment of GFI136N
leukemic cells with HDACis will increase acetylation levels
ofHoxa9 andMeis2. Indeed, inGFI136N heterozygousCbfb-
MYH11-expressing cells, there was an increased level of
H3K9 acetylation at TSSs compared with GFI136S-express-
ing cells (Fig. 5C, two left columns, respectively). Vorinostat
treatment increased H3K9 acetylation levels at both target
promoters (Fig. 5C, two middle columns, respectively),
whereas treatment with CTK7a decreased the H3K9 acetyla-
tion level of GFI136N heterozygous cells to a level similar to
that in GFI136S samples (Fig. 5C, two right columns respec-
tively). These data support our theory with respect to the
action of HDACis and HATis on Gfi1 target genes in
GFI36S- and GFI136N-expressing leukemic cells. They also
recapitulate, on a molecular level, the more pronounced ef-
fect of HATis on GFI136N-expressing leukemic cells.To exclude a general toxic effect of CTK7a, GFI136N/WT
and GFI136S/WT lineage-negative (Lin–) BM cells were
treated with HDACis or HATis. GFI136N/WT and GFI136S/WT
cells responded to the same extent to both inhibitors, and
growth reductionwas by far less evident in nonleukemic cells
compared with leukemic cells (Fig. 5D). Primary AML cells
from GFI136N/36S or GFI136S/36S patients were treated with
Vorinostat or CTK7a (Supplementary Table E1). Similar to
murine leukemic cells, GFI136N/36S human leukemic cells
were less sensitive to HDACi treatment but more sensitive
to HATi treatment than cells from GFI136S-homozygous pa-
tients (Supplementary Figure E10A–F, online only, available
at www.exphem.org).
To test these inhibitors in vivo, we performed secondary
transplantations with GFI136N/WT or GFI136S/WT MLL-AF9-
expressing leukemic cells and treated the recipient mice
with CTK7a or vehicle (DMSO) as control (Fig. 6A).
CTK7a treatment of mice transplanted with GFI136S/WT
MLL-AF9-expressing leukemic cells did not alter their sur-
vival. Recipients of GFI136N/WT leukemic cells treated with
DMSO developed AML in a similar period as recipients of
GFI136S/WT leukemic cells (Supplementary Figure E11, on-
line only, available at www.exphem.org). However, CTK7a
treatment of mice transplanted with GFI136N/WT MLL-AF9
expressing leukemic cells appeared to prolong their sur-
vival (p 5 0.02) (Fig. 6A).
Numerous reports have characterized the function of
leukemic stem cells (LSCs) in different types of leukemia
[23,47–52]; however, with respect to AML, it is generally
accepted that LSCs play a major role in AML initiation
and progression [23,47–51]. Therefore, we next examined
the effect of HATi treatment specifically on LSC function
after ex vivo exposure of leukemic BM cells to CTK7a
treatment followed by transplantation (Fig. 6B). CTK7a
treatment ex vivo did not improve survival or leukemic
burden of mice transplanted with MLL-AF9 GFI136S-ex-
pressing leukemic cells compared with the vehicle-treated
control mice (Fig. 6C–E). However, ex vivo treatment of
GFI136N-expressing MLL-AF9 leukemic cells significantly
delayed AML engraftment (Fig. 6E), as evidenced by the
smaller amounts of GFP-positive cells detected in the PB
at week 5 after transplantation (Fig. 6F). These data suggest
that an epigenetic therapy targeting histone acetylation with
HATis could be beneficial for GFI136N carriers (Fig. 7).
Because we transplanted equal numbers of leukemic cells
after treatment, the effects are not due to the reduced num-
ber of leukemic cells transplanted but to alteration of the
stem cell compartment. In summary, we could prolong sur-
vival of mice with an aggressive type of AML by 25%–30%
just by treating them with a single agent.Discussion
In all murine models of human AML used here, GFI136N
accelerated the development of AML. The extent to which
Figure 5. Epigenetic therapy for GFI136N-associated MDS/AML. (A) Lin–c-Kitþ cells of mice heterozygous for GFI136N or GFI136S were transduced with
the MLL-AF9 retrovirus, and after sorting, the preleukemic cells were treated with either Vorinostat (an HDACi) or CTK7a (an HATi) at the indicated con-
centrations. One representative experiment of three is shown; n 5 3 for each condition. *p 5 0.02. (B) GFI136N-heterozygous or GFI136S-homozygous mu-
rine BM leukemic cells expressing Cbfb-MYH11 oncofusion protein were treated with either Vorinostat or CTK7a. One representative experiment of two is
shown; n 5 3 for each condition. **p! 0.007; ***p 5 0.0009. (C) GFI136S-homozygous or GFI136N-heterozygous cells expressing the oncofusion protein
Cbfb-MYH11 were treated with CTK7a or Vorinostat or left untreated (CTL). Using ChIP, we determined enrichment for H3K9 acetylation at a locus around
the TSS for two genes: Hoxa9 and Meis2. H3K9 acetylation level for the untreated cells expressing GFI136S was set as a reference to 1. *p 5 0.01. (D) Lin–
cells derived from healthy GFI136N/WT or GFI136S/WT mice were isolated and treated with the indicated concentration of Vorinostat or CTK7a; n 5 3 for each
condition. One experiment was performed. (E) GFI136N-heterozygous or GFI136S-homozygous human leukemic cells were treated with either Vorinostat or
CTK7a. One representative experiment of six different human samples is shown; n5 3 for each condition, *p5 0.05, **p5 0.01, and ***p! 0.0005 based
on a two-sided Student t test. Please also see Supplementary Figure E10 and Supplementary Table E1.
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Figure 6. HAT inhibitor is a more effective potential therapeutic strategy for GFI136N AML patients. (A) Schematic of the experimental design (left). Sub-
lethally irradiated mice (3 Gy) were transplanted with leukemic BM cells derived from primary recipient mice previously transplanted with Lin– BM cells
derived from GFI136N/WT or GFI136S/WT mice transduced with a MLL-AF9-expressing retrovirus. The mice were treated either with CTK7a (green dotted for
GFI136N/WT leukemic cells and blue dash for GFI136S/WT leukemic cells) or with vehicle (DMSO) (red for GFI136N/WT and GFI136S/WT leukemic cells). On
the right is the Kaplan–Meier curve of AML-free survival (p5 0.02). (B) Schematic of the experimental design. GFI136N/WT or GFI136S/WT expressing MLL-
AF9 leukemic cells were treated ex vivo with CTK7a or DMSO for 48 hours. Subsequently, the cells were transplanted into sublethally irradiated mice. (C)
Kaplan–Meier curve of AML-free survival for mice transplanted with GFI136S/WT-expressing MLL-AF9 leukemic cells (p 5 0.02). (D) The percentage of
GFPþ cells in the PB at week 6 after transplantation of GFI136S/WT-expressing MLL-AF9 leukemic cells. (E) Kaplan–Meier curve of AML-free survival for
mice transplanted with GFI136N/WT-expressing MLL-AF9 leukemic cells (p 5 0.01). (F) Percentage of GFP-positive cells in the PB at week 5 after
transplantation of GFI136N/WT-expressing MLL-AF9 leukemic cells. *p 5 0.04. ms 5 median survival in days. (Color version of figure available online.)
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Figure 7. Working model for treatment of GFI1-36N-associated AML. In GFI136N AML cells, there is a higher level of acetylation, and HDACis would
increase acetylation beyond this level, leading to oncogene activation that together with additional mutations could lead to AML progression. Treatment
with HATis would equilibrate the level of acetylation that might lead to expression of genes that promote apoptosis or differentiation and, thus, could impede
AML development.
724 L. Botezatu et al./ Experimental Hematology 2016;44:713–726GFI136N accelerated leukemogenesis, however, differed
from one model to another, yet the associated hazard ratios
of the different mouse models were always O2.5, indi-
cating the robustness of our findings and confirming a
role for GFI136N in the development and progression of
myeloid leukemia.
GFI1 directs the differentiation of GMPs [17] and medi-
ates histone modifications, notably H3K9 de-acetylation.
GFI136N is less efficient compared with GFI136S in
inducing H3K9 deacetylation in hematopoietic progenitor
cells. It is likely, that altered levels of H3K9 acetylation,
such as those induced by GFI136N, result in different gene
expression patterns, which contribute to the development
of AML. Our results presented here and our data previously
reported on the effect of GFI136N on Kras-driven myelopro-
liferative diseases [22] support this view. Our data also indi-
cate that the set of genes where histones are differentially
de-acetylated by GFI136N is likely very broad in GMPs. It
is thus conceivable that cells with specific subsets or clus-
ters of genes with altered acetylation patterns might be
selected for during the process of malignant transformation
to form a leukemic clone and that the selected subset of
genes might differ between individual leukemic clones.
Our ChIP-Seq data obtained from different murine and hu-
man leukemic samples would be consistent with such a sit-
uation in which different subsets of genes that are altered
with respect to their histone acetylation patterns appear at
the end of the process of leukemogenesis. The formation
of a variably altered epigenetic landscape in
GFI136N cells might also explain the absence of a clear as-
sociation between GFI136N and a single common somatic
mutation in different AML cohorts. Thus, our data would
be consistent with the notion that GFI136N drives AML
development in cooperation with most or all known driver
mutations and, possibly, other additional changes by ineffi-
cient de-acetylation of a broad range of GFI1 target genes
subsets that favor malignant transformation of myeloid pre-
cursors into different leukemic clones.Therapeutic approaches using HDACis for MDS/AML
still remain experimental and have not been found to have
a clear benefit [53]. One explanation for this might be the
fact that GFI136N carriers are presently treated the same
way as GFI136S-homozygous patients. Although GFI136N
carriers represent only 10%–15% of all AML patients, the
fact that GFI136N carriers are resistant to treatment with
HDACis might mask possible net effects of HDACis or other
therapeutic approaches on GFI136S-homozygous carriers.
Therefore, prospective studies using these inhibitors should
distinguish between GFI136N carriers and GFI136S-homozy-
gous patients. In particular, GFI136S-homozygous patients
might benefit from epigenetic therapy with HDACis differ-
ently than GFI136N carriers. Thus, GFI136N would represent
a marker for additional personalized epigenetic therapy in
combination with the standard therapy used now. Prospec-
tive therapeutic studies with HATis could evaluate whether
GFI136N carriers might profit from such a modified thera-
peutic approach. Our in vitro and in vivo data with both
HDACi and HATi and cells expressing GFI136N would sup-
port such studies. Furthermore, GFI136N/WT nonleukemic
Lin– BM cells were not affected by the CTK7a treatment
to the same extent as GFI136N leukemic cells. This differ-
ence might open a therapeutic window for GFI136N patients
with a different response of nonmalignant and malignant
cells to HATis therapy. It remains to be examined, in pro-
spective studies, how either GFI136S-homozygous or
GFI136N-heterozygous or -homozygous patients differ with
respect to the response to HDACis and whether the use of
HATis might be more beneficial for GFI136N-heterozygous
or -homozygous patients. Our data are in line with other
recent work suggesting that epigenetic therapy could be
beneficial for leukemia [54]. However, our data indicate
that this has to be performed in a personalized manner.
GFI136N status can be determined using basic laboratory
equipment, making it an attractive biomarker. Because
HDACis are also used for multiple myeloma or T-cell lym-
phoma, GFI136N might be a therapeutic marker in these
725L. Botezatu et al./ Experimental Hematology 2016;44:713–726cases. Furthermore, we have indications that GFI136N might
play a role in chronic myeloid leukemia or in pediatric
MDS. Because Gfi1 plays also an important role in lung
and gut development [55–60], it would be interesting to
investigate whether GFI136N could be involved in similar
epigenetic changes that might lead to malignant diseases
of the lung or gut. In summary, GFI136N could open
a new personalized treatment approach to myeloid
malignancy patients and, possibly, other entities.Acknowledgments
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Supplementary materials and methods
Retroviral transduction and transplantation of murine he-
matopoietic progenitors. The MCSV-MLL-AF9-IRES-
GFP (MLL-AF9) vector was generously provided by
Dr. Jay Hess. The AML1-ETO9a vector was kindly pro-
vided by Dr. Lee Grimes. Ectopic retroviral supernatants
were produced by transient co-transfection of 293Tmyc
cells with 2.25 mg pCL-Eco retroviral packaging vector
(IMGENEX) and 20 mg retroviral plasmid DNA using stan-
dard calcium phosphate precipitation methods. The viral
supernatants were titrated on murine NIH3T3 cells. Retro-
viral transduction of lineage negative (Lin–) or Lin–c-Kitþ
cells was done on days 3 and 4 after isolation. Viral super-
natants were centrifuged twice onto retronectin-coated (Ta-
kara Bio) non–tissue culture-treated plates at $4,600 rpm
for $90 min at 4C. After removal of viral supernatants
from the retronectin-coated wells, Lin– or Lin–c-kitþ cells
were added to the plates, and after these were spun down
for 10 min at 1,200 rpm at 4C, 2 mg/mL polybrene infec-
tion/transfection reagent (Millipore) was added to the cells.
On day 5 after isolation, 1  105 GFP-positive cells were
injected intravenously into lethally irradiated recipient
mice together with 1.5  105 competitive BM cells.
ChIP, ChIP-Seq, and RNA-Seq analysis. For ChIP
sequencing, libraries were prepared from immunoprecipi-
tated chromatin samples using the TruSeq DNA kit from Il-
lumina, according to the manufacturer’s instructions, and
sequenced using the TruSeq PE Clusterkit v3-cBot-HS on
an Illumina HiSeq 2000 system. Reads were aligned to
the mouse reference mm10 genome using Bowtie2 Version
2.10 [26]. Reads were processed, and duplicates were
removed using Samtools; promoter coverage for heat
maps was generated using the annotatePeaks.pl function
of the Homer Software. The DiffBind R package was
used to quantify changes in acetylation levels on gene
promoters.
For RNA sequencing, libraries were prepared from RNA
extracts using the Illumina TruSeq Stranded mRNA Kit, ac-
cording to the manufacturer’s instructions, and sequenced
using the TruSeq PE Clusterkit v3-cBot-HS on an Illumina
HiSEq 2000 system. Sequencing reads were aligned to the
mm10 genome using Tophat Version 2.0.10. Reads were
processed with Samtools and then mapped to Ensembl tran-
scripts using HTSeq. Differential expression was tested us-
ing the DESeq R package (R Coding Team).
The ChIP-Seq and RNA-Seq data used are available
on the GEO database under Record Nos. GSE31657,
GSE71254, and GSE77073.
The primer sequences for ChIP used to determine the ef-
fect of different epigenetic inhibitors on Hoxa9 and Meis2
loci are:
js_HoxA9pro_F3: CCACGCTTGACACTCACACT
js_HoxA9pro_R3: TCGCTGGGTTGTTTTTCTCT
Meis 2 F: CAAGGTCGGGTACAAGGTGT
Meis 2 R: AACCCAGGGAGAAGTGGAGT
Isolation and culture of hematopoietic progenitors. BM
cells were isolated from femurs, tibias, and humeri of 8-
to 12-week-old mice. Lin– BM cells were separated using
the Lineage Cell Depletion Kit for mouse (Miltenyi Biotec)
according to the manufacturer’s instructions. Lin– cells,
when used for transplantation, were cultured in Marrow
Max Bone Marrow Medium (GIBCO) supplemented with
20 ng/mL recombinant mouse stem cell factor (Miltenyi
Biotec), 10 ng/mL recombinant mouse interleukin-3 (Milte-
nyi Biotec), and 10 ng/mL recombinant human interleukin-
6 (Miltenyi Biotec). For in vitro studies, Lin– cells were
cultured in stem cell medium (Iscove’s modified Dulbec-
co’s medium, GIBCO) supplemented with 20% fetal bovine
serum (PAN Biotech GmbH), 1% penicillin–streptomycin
(Sigma), and the same cytokines at the same concentrations
mentioned above. For sorting of Lin–c-Kitþ cells, freshly
isolated Lin– cells were stained with Biotin Mouse Lineage
Depletion Cocktail (BD Biosciences), biotin-conjugated
mouse CD16/32 (BD Biosciences), phycoerythrin-
conjugated anti-mouse CD117 (c-kit, Biolegend), and
streptavidin-conjugated PerCP-Cy5.5 (eBioscience) and
were sorted using a FACS DIVA Cell Sorter (BD
Biosciences).
In vitro liquid culture and colony assays. For liquid cul-
ture, 3,000–5,000 sorted GFP-positive cells were cultured
in triplicate in 150 mL stem cell medium in 96-well non-
tissue culture-treated plates. Every 2 days 50 mL fresh me-
dium was added to each well, and after 5–7 days of culture,
the cells were counted. For colony assay, approximately
1,000 sorted GFP-positive cells were seeded in methylcel-
lulose medium M3434 (Stem Cells). Colony formation, as
well as the cell number, was assessed 7 to 10 days later.
Immunoprecipitation. Protein immunoprecipitation was
performed as previously described [22]. Briefly, 293T cells
were transduced with expression plasmids of the indicated
proteins. The antibodies Gfi1 antibody (sc-22796), HDCA1
antibody (sc-1598), and HDCA2 antibody (sc-9959) were
ordered from Santa Cruz (Dallas, TX). Protein complexes
were precipitated using protein A–agarose immunoprecipi-
tation beads (Roche Diagnostic).
Quantitative reverse transcription PCR. Total RNA was
extracted from leukemic BM cells using an RNeasy Mini-
Kit or RNeasy MicroKit (Qiagen) according to the manu-
facturer’s instructions. A Nanometer P-class USB
microphotometer (Implen) was used to measure the amount
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and purity of the RNA. First-strand cDNA was generated
using a Clontech Laboratories PCR kit (Takara), according
to the manufacturer’s instructions. The analysis was
performed using the Real Time PCR system OneStep
(Applied Biosystems, Thermo Fisher Scientific). The
following TaqMan primers (Applied Biosystems) were
used: Gfi1 (Mm00515853_m1) and GFI1
(Hs00382207_m1). Gene expression was normalized to
Gapdh1 (Mm03302249_g1) using the DDCt method.
726.e2 L. Botezatu et al./ Experimental Hematology 2016;44:713–726
Supplementary Table E1. Characteristics of patient samples used for ChIP-Seq analysis and drug treatment
Patient Age Sex
Genotype
GFI136 Cytogenetic Mutation Source
1 31 F S/S 45, XX,inv(3) (p21q26), 7 [26] BM
2 76 M N/S 47,XY,þ?add(8)(p21) PB
3 59 M S/S 46, XY PB
4 65 M N/S 46,XY BM
5 69 F S/S Normal FLT-ITD pos PB
6 72 F N/S Normal FLT-ITD pos PB
7 76 F S/S 46,XX,t(15;17)(q22;q21) [27] PB
8 49 F N/S 46XX, t(15;17), t(4;11) PB
9 64 M S/S Normal BM
10 68 M N/S Normal BM
11 66 M N/S Normal NPM mutated PB
12 70 M N/S Normal NPM mutated PB
N/S 5 heterozygous for GFI136S and GFI136N; S/S 5 homozygous for GFI136S; FLT-ITD5FLT3 internal tandem duplication; PB 5 peripheral blood;
BM 5 bone marrow.
Samples 1-8 were used for drug studies, and samples 9–12 for ChIP-Seq.
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Supplementary Figure E1. Median values for hemoglobin (A), red blood cell (RBC) number (B), platelet number (C), and WBC number (D) of healthy
control mice at age 5–8 months (n5 5) and the combined cohort of GFI136N and GFI136S MLL-AF9-expressing leukemic mice (n5 10). (E) Photographs of
PB smears, BM, and spleen (SPL) cytospins for the indicated genetic background. Bar 5 20 mm.
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Supplementary Figure E2. Median values for hemoglobin (A), RBC number (B), platelet number (C), and WBC number (D) of healthy control mice at age
5–8 months (n 5 5) and the combined cohort of GFI136N and GFI136S NUP98-HOXD13 expressing leukemic mice (n 5 46). **p! 0.001; ***p! 0.0001.
(E) Photographs of PB smears, BM, and SPL cytospins for the indicated genetic background. Bar 5 20mm.
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Supplementary Figure E3. Median values for hemoglobin (A), RBC number (B), platelet number (C), and WBC number (D) of healthy control mice at
age 5–8 months (n 5 5) and the combined cohort of GFI136N and GFI136S Cbfb-MYH11-expressing leukemic mice (n 5 50). *p 5 0.001; ***p! 0.0001.
(E) Photographs of PB smears, BM, and SPL cytospins for the indicated genetic background.
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Supplementary Figure E4. (A) UCSC genome browser views indicating H3K9 acetylation levels of Cbfb-MYH11 expressing leukemic cells for the indi-
cated genotypes. (B) UCSC genome browser views indicating number of reads in the RNA-Seq of Cbfb-MYH11-expressing leukemic cells for the indicated
genotypes.
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Supplementary Figure E5. (A) GO biological functions overrepresented among genes indicating decreased acetylation in GFI136N murine leukemic sam-
ples compared with GFI136S murine samples, as determined using DAVID software. The p value was used to rank enrichment. (B) Scatterplot comparing the
log2-fold change in H3K9ac ChIP-seq between GFI1
36S- and GFI136N-expressing Cbfb-MYH11 murine BM leukemic cells versus change in mRNA levels
between GFI136S- and GFI136N-expressing Cbfb-MYH11 BM leukemic cells in three pairs of samples.
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Supplementary Figure E6. (A) UCSC genome browser views indicating read distributions for GFI1 ChIP-seq and IgG ChIP-seq experiments with murine
hematopoietic progenitor cells immortalized by retroviral transduction of an MLL-ENL expression vector (GSE31657). The IgG ChIP-seq is a control to
exclude unspecific binding. The lower panel represents read distributions for H3K9ac ChIP-seq in GFI136N/WT (in red) and GFI136S/WT (in blue) leukemic
cells over the Meis2 promoter. To the right is the expression level of the indicated gene as determined by RT-PCR on the same samples that were used for
ChIp-Seq. ***p 5 0.0005; ****p ! 0.0001. (B) As in (A), over the Tcf4 promoter region. (C) As in (A), over the Irf8 promoter region. kb 5 kilobases.
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Supplementary Figure E7. (A) GO biological functions overrepresented
among genes, indicating decreased acetylation in GFI136N human
leukemic samples compared with GFI136S human samples, as determined
using DAVID software. The p value was used to rank enrichment. (B) Scat-
terplot comparing the log2-fold change in H3K9ac ChIP-seq between
GFI136S and GFI136N AML samples versus the change in mRNA levels be-
tween GFI136S and GFI136N AML in two pairs of samples.
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Supplementary Figure E8. (A) Immunoprecipitation (IP) using 293T- extracts overexpressing either GFI136S or GFI136N with the indicated antibodies. In
this approach, the interaction between the different variants of GFI1 and HDAC1 is examined. (B) IP using 293T- extracts overexpressing either GFI136S or
GFI136N with the indicated antibodies. In this approach, the interaction between the different variants of GFI1 and HDAC2 is examined.
726.e11L. Botezatu et al./ Experimental Hematology 2016;44:713–726
Supplementary Figure E9. (A) GFI1-RNA expression levels of different types of AML based on published expression arrays from Verhaak et al. [42]
(n 5 17 for MLL-AF9–induced AML, n 5 21 for Inv 16, n 5 129 for AML with no cytogenetic aberration, and n 5 29 for PML-RARa translocation).
(B) GFI1-RNA expression levels of GFI136N-heterozygous (n 5 16) or GFI136S-homozygous (n 5 172) human leukemic blasts as published by Valk
et al. [43] and Khandanpour et al. [21]. (C) Murine Gfi1-RNA expression levels of GFI136N- or GFI136S-heterozygous (the other allele being murine
Gfi1) murine leukemic blasts of MLL-AF9–induced AML. Presented are each of at least two repeated measurements (n 5 3 independent animals for
each condition). (D) Murine Gfi1-RNA expression levels of GFI136N- or GFI136S-heterozygous (the other allele being murine Gfi1) murine leukemic blasts
of Cbfb-MYH11-induced AML. Presented are each of at least two repeated measurements (n 5 3 independent animals for each condition). (E) Murine Gfi1-
RNA expression level of GFI136N or GFI136S heterozygous (the other allele being murine Gfi1) murine leukemic blasts of NUP98-HOXD13 transgenic (tg)
mice. Presented are each of at least two repeated measurements (n 5 3 animals for GFI136S heterozygous mice and n 5 2 animals for GFI136N heterozygous
mice). (F) Human GFI1-RNA expression levels of GFI136N- or GFI136S-expressing murine leukemic blasts of MLL-AF9–induced AML. Presented are each
of at least two repeated measurements (n 5 3 animals for GFI136S-expressing mice and n 5 4 animals for GFI136N-expressing mice). (G) Human GFI1-RNA
expression levels of GFI136N- or GFI136S-expressing murine leukemic blasts of Cbfb-MYH11–induced AML. Presented are each of at least two repeated
measurements (n 5 4 animals for GFI136S-expressing mice and n 5 3 animals for GFI136N-expressing mice). (H) Human GFI1-RNA expression level of
GFI136N or GFI136S expressing murine leukemic blasts of NUP98-HOXD13 tg mice. Presented are each of at least two repeated measurement (n5 2 animals
for GFI136S-expressing mice and n 5 3 animals for GFI136N-expressing mice).
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Supplementary Figure E10. (A) Treatment of two patient samples either homozygous or heterozygous for GFI136S with Vorinostat for 48 hours. Depicted is
the effect of different doses of Vorinostat as numbers of total cells and annexin-negative cells. The numbers were normalized to the vehicle control (DMSO).
(n 5 3 for each measurement in B–F.) (B) Treatment of two additional patient samples either homozygous or heterozygous for GFI136S with Vorinostat for
48 hours. Depicted is the effect of different doses of Vorinostat as number of total cells and annexin negative cells. The numbers were normalized to the
vehicle control (DMSO). (C) Treatment of two patient samples (same as in A) either homozygous or heterozygous for GFI136S with CTK7a for 48 hours.
Depicted is the effect of different doses of CTK7a as numbers of total cells and annexin-negative cells. The numbers were normalized to the vehicle control
(DMSO). (D) Treatment of two additional patient samples (same as in B) either homozygous or heterozygous for GFI136S with CTK7a for 48 hours. Depicted
is the effect of different doses of CTK7a as numbers of total cells and annexin-negative cells. The numbers were normalized to the vehicle control (DMSO).
(E) Treatment of two additional patient samples either homozygous or heterozygous for GFI136S with CTK7a for 48 hours. Depicted is the effect of different
doses of CTK7a as numbers of total cells and annexin-negative cells. The numbers were normalized to the vehicle control (DMSO). No sufficient number of
cells was available after thawing to perform the same experiments with Vorinostat. (F) Treatment of two additional patient samples (same as in E) either
homozygous or heterozygous for GFI136S with CTK7a for 72 hours. Depicted is the effect of different doses of CTK7a as numbers of total cells and
annexin-negative cells. The numbers were normalized to the vehicle control (DMSO). No sufficient number of cells was available after thawing to perform
the same experiments with Vorinostat. *p 5 0.05. **p 5 0.01. ***p 5 0.001.
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Supplementary Figure E11. GFI136N- or GFI136S-expressing leukemic cells, retrovirally expressing MLL-AF9, were transplanted in sublethally irradiated
mice. The transplanted mice died within a very similar period.
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